Table 2.
Cox proportional hazards regression for association of pretreatment antibody status with overall and progression-free survival among 209 patients with OPC, 130 patients with ≤10 pack-years of smoking, and 96 patients with tumor HPV-positive OPC.
| All patients N=209 |
Patients with ≤10 pack years N=130 |
Tumor HPV-positive patients N=96 |
||||
|---|---|---|---|---|---|---|
| Crude HR (95% CI) |
Adjusted HR (95% CI) |
Crude HR (95% CI) |
Adjusted HR (95% CI) |
Crude HR (95% CI) |
Adjusted HR (95% CI) |
|
| Overall survivala | ||||||
| E1+ vs. E1 − | 0.3 (0.1–0.5) | 0.3 (0.2–0.5) | 0.5 (0.2–1.3) | 0.5 (0.2–1.4) | 0.2 (0.1–0.6) | 0.3 (0.1–0.7) |
| NE2+ vs. NE2− | 0.2 (0.1–0.3) | 0.2 (0.1–0.4) | 0.3 (0.1–1.2) | 0.5 (0.1–1.8) | 0.1 (0.1–0.3) | 0.2 (0.1–0.6) |
| CE2+ vs. CE2− | 0.4 (0.2–0.8) | 0.5 (0.2–1.0) | 0.8 (0.3–2.1) | 0.8 (0.3–2.1) | 0.5 (0.2–1.4) | 0.6 (0.2–1.6) |
| E4+ vs. E4− | 0.5 (0.2–1.2) | 0.4 (0.2–1.0) | 0.2 (0–1.4) | 0.2 (0–1.6) | 0.2 (0–1.6) | 0.3 (0–2.2) |
| E5+ vs. E5− | NC | NC | NC | NC | NC | NC |
| E6+ vs. E6− | 0.2 (0.1–0.4) | 0.3 (0.2–0.6) | 0.3 (0.1–0.8) | 0.5 (0.2–1.3) | 0.3 (0.1–0.7) | 0.3 (0.1–0.9) |
| E7+ vs. E7− | 0.5 (0.3–1.0) | 0.7 (0.3–1.3) | 1.3 (0.4–3.9) | 1.2 (0.4–3.8) | 0.6 (0.2–1.5) | 0.9 (0.3–2.6) |
| Any E+ vs. all − | 0.2 (0.1–0.3) | 0.2 (0.1–0.4) | 0.1 (0–0.8) | 0.1 (0–0.7) | 0.1 (0.1–0.4) | 0.3 (0.1–0.9) |
| Progression-free survivalb | ||||||
| E1+ vs. E1 − | 0.3 (0.2–0.6) | 0.4 (0.2–0.7) | 0.7 (0.3–1.8) | 0.7 (0.3–1.9) | 0.3 (0.10–0.7) | 0.3 (0.1–0.7) |
| NE2+ vs. NE2− | 0.2 (0.1–0.4) | 0.3 (0.1–0.5) | 0.5 (0.1–1.6) | 0.5 (0.1–1.8) | 0.1 (0.05–0.3) | 0.2 (0.1–0.6) |
| CE2+ vs. CE2− | 0.5 (0.3–0.9) | 0.5 (0.3–1.0) | 1.0 (0.4–2.4) | 1.1 (0.4–2.6) | 0.5 (0.19–1.3) | 0.5 (0.2–1.4) |
| E4+ vs. E4− | 0.5 (0.2–1.2) | 0.4 (0.2–1.0) | 0.3 (0.1–1.4) | 0.3 (0.1–1.4) | 0.4 (0.09–1.8) | 0.5 (0.1–2.3) |
| E5+ vs. E5− | NC | NC | NC | NC | NC | NC |
| E6+ vs. E6− | 0.3 (0.2–0.5) | 0.4 (0.2–0.7) | 0.4 (0.2–1.0) | 0.5 (0.2–1.5) | 0.3 (0.11–0.7) | 0.3 (0.1–0.9) |
| E7+ vs. E7− | 0.6 (0.3–1.0) | 0.6 (0.4–1.2) | 1.3 (0.5–3.7) | 1.8 (0.6–5.4) | 0.5 (0.19–1.2) | 0.7 (0.3–1.9) |
| Any E+ vs. all- | 0.2 (0.1–0.4) | 0.2 (0.1–0.5) | 0.2 (0–1.3) | 0.1 (0–1.0) | 0.1 (0.05–0.4) | 0.3 (0.1–0.8) |
a
All patients: adjusted for age, smoking, and treatment; Patients with ≤10 pack-years: adjusted for age and treatment; HPV-positive patients: Adjusted for age, smoking, and T category.
b
All patients: adjusted for age, smoking, and treatment; Patients with ≤10 pack-years: adjusted for age, N category, and treatment; HPV-positive patients: Adjusted for age, smoking, and T category.
NC: not calculable due to zero cells.